On Monday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) opened higher 3.45% from the last session, before settling in for the closing price of $17.66. Price fluctuations for ACAD have ranged from $14.15 to $32.59 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.73%. Company’s average yearly earnings per share was noted 293.24% at the time writing. With a float of $165.12 million, this company’s outstanding shares have now reached $166.39 million.
Let’s determine the extent of company efficiency that accounts for 598 employees. In terms of profitability, gross margin is 91.61%, operating margin of 12.08%, and the pretax margin is 14.71%.
Acadia Pharmaceuticals Inc (ACAD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Acadia Pharmaceuticals Inc is 0.76%, while institutional ownership is 96.97%. The most recent insider transaction that took place on Aug 19 ’24, was worth 148,720. In this transaction EVP, CHIEF FINANCIAL OFFICER of this company sold 9,733 shares at a rate of $15.28, taking the stock ownership to the 43,735 shares. Before that another transaction happened on Aug 19 ’24, when Company’s EVP, COO, HEAD OF COMMERCIAL sold 9,534 for $15.28, making the entire transaction worth $145,680. This insider now owns 52,177 shares in total.
Acadia Pharmaceuticals Inc (ACAD) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 293.24% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Check out the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). In the past quarter, the stock posted a quick ratio of 2.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.36. Likewise, its price to free cash flow for the trailing twelve months is 15.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.21 in the next quarter and is forecasted to reach 0.78 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Looking closely at Acadia Pharmaceuticals Inc (NASDAQ: ACAD), its last 5-days average volume was 2.04 million, which is a jump from its year-to-date volume of 1.69 million. As of the previous 9 days, the stock’s Stochastic %D was 90.68%. Additionally, its Average True Range was 0.61.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 77.88%, which indicates a significant decrease from 90.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.24% in the past 14 days, which was lower than the 49.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.48, while its 200-day Moving Average is $17.66. However, in the short run, Acadia Pharmaceuticals Inc’s stock first resistance to watch stands at $18.68. Second resistance stands at $19.09. The third major resistance level sits at $19.47. If the price goes on to break the first support level at $17.89, it is likely to go to the next support level at $17.51. Now, if the price goes above the second support level, the third support stands at $17.10.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
There are currently 165,876K shares outstanding in the company with a market cap of 3.12 billion. Presently, the company’s annual sales total 726,440 K according to its annual income of -61,290 K. Last quarter, the company’s sales amounted to 241,960 K and its income totaled 33,390 K.
